Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C4HE | ISIN: US29415J1060 | Ticker-Symbol: 5HJ
Frankfurt
06.06.25 | 08:01
3,000 Euro
-5,06 % -0,160
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ENVVENO MEDICAL CORPORATION Chart 1 Jahr
5-Tage-Chart
ENVVENO MEDICAL CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
3,3203,46006.06.

Aktuelle News zur ENVVENO MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrenVVeno Medical Corporation: Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery 2025 Vascular Annual Meeting184Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit at 24 months compared to baseline83% of subjects maintained...
► Artikel lesen
20.05.enVVeno Medical Corp - 8-K, Current Report1
19.05.enVVeno Medical ernennt neuen CFO2
19.05.enVVeno Medical appoints Jennifer Bright as financial chief2
19.05.enVVeno Medical appoints new CFO amid growth phase2
19.05.enVVeno Medical Corporation: enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer179IRVINE, CA / ACCESS Newswire / May 19, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease...
► Artikel lesen
ENVVENO MEDICAL Aktie jetzt für 0€ handeln
14.05.EnVVeno has first-in-human heart valve data, expects FDA decision this year2
13.05.enVVeno Medical Corporation: Three-Year VenoValve First-in-Human Trial Data Published in the Annals of Vascular Surgery218Promising results from the first-in-human study demonstrated that, at three-years post implantation, VenoValve remained safe and effective--achieving a high rate of patency, restoring deep venous competence...
► Artikel lesen
01.05.enVVeno Medical reports Q1 results2
01.05.enVVeno Medical Corporation: enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24212Cash Burn of $4.0 million in Q1 remains in line with projected quarterly rangeCash and investments on hand are sufficient to fund operations beyond the anticipated FDA decision of VenoValve and the...
► Artikel lesen
30.04.enVVeno Medical Corp - 10-Q, Quarterly Report1
23.04.enVVeno Medical Corporation: VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium126IRVINE, CA / ACCESS Newswire / April 23, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease...
► Artikel lesen
21.04.enVVeno Medical Corp - 8-K, Current Report1
16.04.enVVeno Medical Corporation: enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment212Moderated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Tuesday, April 22nd at 4:00 PM ET IRVINE, CA / ACCESS Newswire / April 16, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO)...
► Artikel lesen
31.03.enVVeno Medical Corporation: The Impact of the VenoValve on Patients with Primary and Secondary Chronic Venous Insufficiency to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium157IRVINE, CA / ACCESS Newswire / March 31, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today...
► Artikel lesen
12.03.enVVeno Medical Corp - S-8, Securities to be offered to employees in employee benefit plans-
03.03.enVVeno Medical reports Q4 results1
28.02.enVVeno Medical Corp - 10-K/A, Annual Report-
28.02.enVVeno Medical Corporation: enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25251Cash Burn of $5.2 million in Q4 remains in line with projected $4-5 million quarterly rangeCash and investments on hand are sufficient to fund operations beyond the anticipated regulatory approval of...
► Artikel lesen
28.02.enVVeno Medical Corp - 10-K, Annual Report1
Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1